Fate Therapeutics FATE
NASDAQ FATE
$2.09 +0.02 (+0.97%)
As of: Oct 22, 2026 · 2:26 PM EDT

Fate Therapeutics (FATE) Ending Cash Balance (2016 - 2018)

Updated

Analysis

Fate Therapeutics (FATE) Ending Cash Balance (2016 - 2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Ending Cash Balance (Qtr)
1 Eli Lilly 1,171.69 Bn 1,140.28 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 649.22 Bn 569.08 Bn 17.30 Bn 16.91 Bn
3 AbbVie 504.17 Bn 477.29 Bn 12.70 Bn 6.57 Bn
4 Merck 366.35 Bn 320.73 Bn 12.21 Bn 6.89 Bn
5 Novartis Ag 303.54 Bn 267.53 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 269.49 Bn 243.18 Bn 12.86 Bn 4.88 Bn
7 Amgen 242.61 Bn 198.01 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 195.09 Bn 169.29 Bn 6.22 Bn 3.18 Bn
9 Pfizer 172.48 Bn 119.12 Bn 10.94 Bn 1.03 Bn
10 Fate Therapeutics 252.23 Mn 98.43 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2018 36.39 Mn
Dec 31, 2017 89.07 Mn
Jun 30, 2017 31.19 Mn
Dec 31, 2016 88.73 Mn
API Access

Fate Therapeutics Ending Cash Balance API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ending-cash-balance&ticker=FATE&period=max&api_key=YOUR_API_KEY